Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma in Mayo Clinic-Led Study

ROCHESTER, Minn. — The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology. "Ixazomib is an investigational, oral proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral [...]
Source: Mayo Clinic Rochester News - Category: Hospital Management Source Type: news